News and updates

The UK government says the price the NHS pays for drugs will not be on the negotiating table. But the devil will be in the detail.

At $2.1m, Zolgensma is the most expensive drug in the world. For many babies with spinal muscular atrophy, the only chance of treatment with this life-saving drug is a lottery where some will be lucky, but others won’t.

Let’s pin down our candidates on the questions that matter.

Watch our video to find out how we won the campaign for cystic fibrosis drug Orkambi - and why we won’t rest until we have a system that delivers for all patients.

After years of campaigning and stalled negotiations between the drug company Vertex and NHS, a group of patients and their families decided to take a different strategic route to make cystic fibrosis drug Orkambi available on the NHS.

Christina, one of the parents we've been organising alongside for a Plan B on Orkambi, describes what today means to her and countless other families.

After a four-year long fight campaigners and patient activists welcome the news this morning that the cystic fibrosis drugs, Orkambi and Symkevi will be made available under the NHS to patients in England

Lobbying your MP isn’t always easy - especially for a boater with no post-code! But my experience shows it’s worth persevering, even when the odds are against you.

Private wealth should never come in the way of public health.

Anne was only able to access the treatment she needed after a public campaign brought the price down. Here she explains why she’s supporting the campaign for Plan B on Orkambi.

We’re celebrating the news today that cystic fibrosis drugs Orkambi and Symkevi have been approved for use in Scotland. But what will this mean for the rest of the UK?

Patient leader Fiona explains what a no deal Brexit could mean for patients - and why she’s calling for certainty.

Patient leader Clare had to fight to access treatment. Now she’s supporting others facing similar battles.

A US-UK free trade deal could spell disaster for our NHS. Diarmaid McDonald explains why in the Mirror.

Negotiations with the drug company Vertex have reached stalemate. It’s time for plan B on Orkambi.

Today we learnt the devastating news that cystic fibrosis drugs Orkambi and Symkevi have been deemed too expensive for NHS Scotland. It’s time for the government to take a stand and overturn Vertex’s monopoly.

Emma Robertson argues that changes to medical trial consent processes could improve or even transform cancer research.